COAGULATION FACTOR IX RECOMBINANT HUMAN: 1,066 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
1,066
Total FAERS Reports
20 (1.9%)
Deaths Reported
167
Hospitalizations
1,066
As Primary/Secondary Suspect
6
Life-Threatening
2
Disabilities
First Report: 20110814 · Latest Report: 20250901
What Are the Most Common COAGULATION FACTOR IX RECOMBINANT HUMAN Side Effects?
#1 Most Reported
Haemarthrosis
318 reports (29.8%)
#2 Most Reported
Haemorrhage
261 reports (24.5%)
#3 Most Reported
No adverse event
97 reports (9.1%)
All COAGULATION FACTOR IX RECOMBINANT HUMAN Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Haemarthrosis | 318 | 29.8% | 2 | 48 |
| Haemorrhage | 261 | 24.5% | 1 | 34 |
| No adverse event | 97 | 9.1% | 0 | 4 |
| Traumatic haemorrhage | 62 | 5.8% | 1 | 11 |
| Fall | 61 | 5.7% | 0 | 14 |
| Drug ineffective | 60 | 5.6% | 1 | 6 |
| Muscle haemorrhage | 54 | 5.1% | 0 | 12 |
| Arthralgia | 52 | 4.9% | 0 | 6 |
| Contusion | 52 | 4.9% | 0 | 5 |
| Device issue | 43 | 4.0% | 0 | 0 |
| Product preparation issue | 39 | 3.7% | 0 | 0 |
| Head injury | 33 | 3.1% | 0 | 5 |
| Joint swelling | 32 | 3.0% | 0 | 6 |
| Pain | 31 | 2.9% | 1 | 10 |
| Epistaxis | 29 | 2.7% | 0 | 3 |
| Off label use | 29 | 2.7% | 0 | 6 |
| Limb injury | 24 | 2.3% | 0 | 2 |
| Joint injury | 20 | 1.9% | 0 | 1 |
| Treatment noncompliance | 20 | 1.9% | 0 | 2 |
| Mouth haemorrhage | 19 | 1.8% | 0 | 2 |
Who Reports COAGULATION FACTOR IX RECOMBINANT HUMAN Side Effects? Age & Gender Data
Gender: 1.3% female, 98.7% male. Average age: 27.7 years. Most reports from: US. View detailed demographics →
Is COAGULATION FACTOR IX RECOMBINANT HUMAN Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2011 | 1 | 0 | 0 |
| 2013 | 2 | 0 | 2 |
| 2014 | 7 | 0 | 2 |
| 2015 | 5 | 0 | 2 |
| 2016 | 14 | 0 | 3 |
| 2017 | 30 | 0 | 6 |
| 2018 | 50 | 4 | 10 |
| 2019 | 70 | 1 | 9 |
| 2020 | 36 | 2 | 7 |
| 2021 | 56 | 0 | 11 |
| 2022 | 74 | 1 | 17 |
| 2023 | 136 | 3 | 26 |
| 2024 | 119 | 1 | 34 |
| 2025 | 65 | 0 | 13 |
What Is COAGULATION FACTOR IX RECOMBINANT HUMAN Used For?
| Indication | Reports |
|---|---|
| Factor ix deficiency | 758 |
| Prophylaxis | 239 |
| Product used for unknown indication | 88 |
| Haemorrhage | 65 |
| Haemorrhage prophylaxis | 52 |
| Haemarthrosis | 26 |
| Haemophilia | 25 |
| Factor viii deficiency | 24 |
| Haemostasis | 22 |
| Haemorrhagic diathesis | 8 |
COAGULATION FACTOR IX RECOMBINANT HUMAN vs Alternatives: Which Is Safer?
COAGULATION FACTOR IX RECOMBINANT HUMAN vs COAGULATION FACTOR IX RECOMBINANT HUMAN\ISOPROPYL ALCOHOL
COAGULATION FACTOR IX RECOMBINANT HUMAN vs COAGULATION FACTOR VIIA RECOMBINANT HUMAN
COAGULATION FACTOR IX RECOMBINANT HUMAN vs COBAMAMIDE
COAGULATION FACTOR IX RECOMBINANT HUMAN vs COBICISTAT
COAGULATION FACTOR IX RECOMBINANT HUMAN vs COBICISTAT\DARUNAVIR ETHANOLATE
COAGULATION FACTOR IX RECOMBINANT HUMAN vs COBICISTAT\DARUNAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE
COAGULATION FACTOR IX RECOMBINANT HUMAN vs COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR
COAGULATION FACTOR IX RECOMBINANT HUMAN vs COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE
COAGULATION FACTOR IX RECOMBINANT HUMAN vs COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL
COAGULATION FACTOR IX RECOMBINANT HUMAN vs COBIMETINIB
Official FDA Label for COAGULATION FACTOR IX RECOMBINANT HUMAN
Official prescribing information from the FDA-approved drug label.